Compare Cassava Sciences Inc (FLNA) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.84 (market cap $2.06B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares is far larger — about 52.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 10,528,006). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| FLNA | TMF | |
|---|---|---|
Market Cap | $39.40M | $2.06B |
Volume | 759,018 | 10,528,006 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $44.14 |
52-Week Low | $0.68 | $25.19 |
Typical Hold Time | 37 Days | 28 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.23, down 0.51% with elevated trading volume of 5.2 million shares. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oversold RSI readings suggest potential for near-term bounce. The ETF saw increased investor interest amid bond market volatility.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. Current oversold conditions may present tactical opportunities, though the bearish technical structure and interest rate sensitivity require careful risk management for investors seeking directional bond exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
